Cytosorbents Corporation (CTSO)

Market Cap	19.89M -67.2%
Revenue (ttm)	37.22M +3.1%
Net Income	-18.21M
EPS	-5.82
Shares Out	3.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,919
Open	6.74
Previous Close	6.85
Day's Range	6.11 - 6.98
52-Week Range	6.00 - 20.80
Beta	1.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammator...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 129
• Stock Exchange: NASDAQ
• Ticker Symbol: CTSO
• Website: https://www.cytosorbents.com

Financial Performance

In 2025, Cytosorbents's revenue was $37.06 million, an increase of 4.12% compared to the previous year's $35.60 million. Losses were -$8.20 million, -60.43% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 10, 2026

Data Sources Report a data error